IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results From a Multicenter Phase 1 Trial

[Anonymous]

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019; 17 (2): 10

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索